

## **WHO-PQ RECOMMENDED SUMMARY OF PRODUCT CHARACTERISTICS**

*This summary of product characteristics focuses on uses of the medicine covered by WHO's Prequalification Team - Medicines. The recommendations for use are based on WHO guidelines and on information from stringent regulatory authorities.\**

*The medicine may be authorised for additional or different uses by national medicines regulatory authorities.*

---

\*[https://extranet.who.int/prequal/sites/default/files/document\\_files/75%20SRA%20clarification\\_Feb2017\\_newtempl.pdf](https://extranet.who.int/prequal/sites/default/files/document_files/75%20SRA%20clarification_Feb2017_newtempl.pdf)

## 1. NAME OF THE MEDICINAL PRODUCT

[HP028 trade name]†

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 60 mg daclatasvir (as dihydrochloride).

*Excipient with known effect:*

Each tablet contains 116 mg of anhydrous lactose

For a full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Film-coated tablet.

White to off-white, round, biconvex film-coated tablet, debossed with 'D' and '6' on either side of the break line on one side and plain on the other side.

The break line is intended for subdivision of tablets when half a tablet dose is to be administered.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

[HP028 trade name] is indicated in combination with sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection in adults and children.

Treatment regimens should follow the most recent WHO treatment guidelines, supplemented by other authoritative guidelines.

### 4.2 Posology and method of administration

Treatment with [HP028 trade name] should be initiated and monitored by a health care provider experienced in the management of chronic hepatitis C.

#### *Posology*

[HP028 trade name] must be given together with sofosbuvir.

[HP028 trade name] is taken once a day by mouth, and the recommended dose depends on body weight, as follows:

| Body weight              | Regimen and duration*              | Daily dose of daclatasvir |
|--------------------------|------------------------------------|---------------------------|
| <i>All genotypes</i>     |                                    |                           |
| 14 kg to less than 26 kg | <i>use alternative formulation</i> | <i>30 mg</i>              |
| 26 kg or more            | 1 tablet per day for 12 weeks      | 60 mg                     |

\* Treatment for 24 weeks is recommended in those who are treatment experienced or who have compensated cirrhosis. It may also be considered in settings where genotype 3 is known to be highly prevalent (>10%).

[HP028 trade name] can be used in patients co-infected with human immunodeficiency virus (HIV).

---

† Trade names are not prequalified by WHO. This is the national medicines regulatory agency's responsibility.

### **Dose recommendation for concomitant medicines**

#### *Strong inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4)*

An alternative product allowing administration of half the dose of daclatasvir (e.g. 30 mg once daily for patients weighing 26 kg or more) should be used if co-administration with strong inhibitors of CYP3A4 is necessary.

#### *Moderate inducers of CYP3A4*

An alternative product allowing administration of a higher dose daclatasvir (e.g. 90 mg once daily for patients weighing 26 kg or more) should be used if co-administration with moderate inducers of CYP3A4 is necessary.

### **Missed doses**

Patients should be instructed that, if they miss a dose of [HP028 trade name], the dose should be taken as soon as possible if remembered within 20 hours of the scheduled dose time. However, if the missed dose is remembered more than 20 hours after the scheduled dose, the dose should be skipped, and the next dose taken at the appropriate time.

### **Special populations**

#### *Elderly*

No dose adjustment of [HP028 trade name] is required for patients aged  $\geq 65$  years (see section 5.2).

#### *Renal impairment*

No dose adjustment of [HP028 trade name] is required for patients with any degree of renal impairment (see section 5.2).

#### *Hepatic impairment*

No dose adjustment of [HP028 trade name] is required for patients with any degree of hepatic impairment (see sections 4.4 and 5.2).

### **Method of administration**

[HP028 trade name] is to be taken orally with or without food. Patients should be instructed to swallow the tablet whole. The tablet should not be chewed or crushed due the unpleasant taste of the active substance.

### **4.3 Contraindications**

[HP028 trade name] should not be given to patients with hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

[HP028 trade name] should not be co-administered with medicinal products that strongly induce cytochrome P450 3A4 (CYP3A4) and/or P-glycoprotein transporter (P-gp) as these substances may lead to lower exposure and loss of efficacy of [HP028 trade name]. These active substances include but are not limited to phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, systemic dexamethasone, and the herbal product St John's wort (*Hypericum perforatum*).

### **4.4 Special warnings and precautions for use**

[HP028 trade name] must be given with sofosbuvir (see sections 4.1 and 4.2).

#### ***Severe bradycardia and heart block***

Cases of severe bradycardia and heart block have been observed when daclatasvir is used in combination with sofosbuvir and concomitant amiodarone with or without other drugs that lower heart rate. The mechanism is not established.

The concomitant use of amiodarone was limited through the clinical development of sofosbuvir plus direct-acting antivirals (DAAs). Cases are potentially life threatening, therefore amiodarone should only be used in

patients on daclatasvir and sofosbuvir when other alternative antiarrhythmic treatments are not tolerated or are contraindicated. Should concomitant use of amiodarone be considered necessary it is recommended that patients are closely monitored when initiating daclatasvir in combination with sofosbuvir. Patients who are identified as being at high risk of bradyarrhythmia should be continuously monitored for 48 hours in an appropriate clinical setting.

Due to the long half-life of amiodarone, appropriate monitoring should also be carried out for patients who have discontinued amiodarone within the past few months and are to be initiated on daclatasvir in combination with sofosbuvir.

All patients receiving daclatasvir and sofosbuvir in combination with amiodarone with or without other drugs that lower heart rate should also be warned of the symptoms of bradycardia and heart block and should be advised to seek medical advice urgently should they experience them.

#### ***HCV/HBV (hepatitis B virus) co-infection***

Cases of hepatitis B virus (HBV) reactivation, some of them fatal, have been reported during or after treatment with direct-acting antiviral agents. HBV screening should be performed in all patients before initiation of treatment. HBV/HCV co-infected patients are at risk of HBV reactivation, and should therefore be monitored and managed according to current clinical guidelines.

#### ***Retreatment with daclatasvir***

The efficacy of [HP028 trade name] as part of a retreatment regimen in patients with prior exposure to a NS5A inhibitor has not been established.

#### ***Pregnancy and contraception requirements***

[HP028 trade name] should not be used during pregnancy or in women of childbearing potential not using contraception. Use of highly effective contraception should be continued for 5 weeks after completion of [HP028 trade name] therapy (see section 4.6).

#### ***Interactions with medicinal products***

[HP028 trade name] can alter the concentration of other medicinal products if given at the same time, and other medicinal products may alter the concentration of daclatasvir. See section 4.3 and section 4.5 for further information.

#### ***Use in patients with diabetes***

Patients with diabetes may experience improved glucose control, potentially resulting in symptomatic hypoglycaemia, after beginning HCV DAA treatment. Glucose levels of diabetic patients starting DAA therapy should be closely monitored, particularly within the first 3 months, and their diabetic medication modified when necessary. The health care provider in charge of the diabetic care of the patient should be informed when DAA therapy is started.

#### ***Excipients***

The small amount of lactose in each dose is unlikely to cause symptoms of lactose intolerance.

It is important to consider the contribution of excipients from all the medicines that the patient is taking.

### **4.5 Interaction with other medicinal products and other forms of interaction**

#### ***Potential for interaction with other medicinal products***

Daclatasvir is a substrate of CYP3A4, P-gp and organic cation transporter (OCT) 1 and an inhibitor of P-gp, organic anion transporting polypeptide (OATP) 1B1, OCT1 and breast cancer resistance protein (BCRP).

#### ***Effects on daclatasvir***

Strong or moderate **inducers** of CYP3A4 and P-gp may decrease the plasma levels and therapeutic effect of [HP028 trade name]. Co-administration with strong inducers of CYP3A4 and P-gp is contraindicated (see

section 4.3), while dose adjustment of [HP028 trade name] is recommended when co-administered with moderate inducers of CYP3A4 and P-gp (see table below).

Strong **inhibitors** of CYP3A4 may increase the plasma levels of [HP028 trade name]. Dose adjustment of [HP028 trade name] is recommended when co-administered with strong inhibitors of CYP3A4 (see table below).

Co-administration of medicines that inhibit P-gp or OCT1 activity is likely to have a limited effect on daclatasvir exposure.

*Effects on co-administered drugs*

Administration of [HP028 trade name] may increase systemic exposure to medicinal products that are substrates of P-gp, OATP 1B1, OCT1 or BCRP, which could increase or prolong their therapeutic effect and adverse reactions. Caution should be used if the medicinal product has a narrow therapeutic range (see table below).

Daclatasvir is a very weak inducer of CYP3A4 and caused a 13% decrease in midazolam exposure. However, as this is a limited effect, dose adjustment of concomitantly administered CYP3A4 substrates is not necessary.

Refer to the respective Summary of Product Characteristics for drug interaction information for other medicinal products in the regimen.

*Patients treated with vitamin K antagonists*

As liver function may change during treatment with [HP028 trade name], a close monitoring of International Normalized Ratio (INR) values is recommended.

**Tabulated summary of interactions**

The table below provides information from drug interaction studies with daclatasvir including clinical recommendations for established or potentially significant drug interactions. Clinically relevant increase in concentration is indicated as “↑”, clinically relevant decrease as “↓”, no clinically relevant change as “↔”. If available, ratios of geometric means are shown, with 90% confidence intervals (CI) in parentheses. The studies presented in the table were conducted in healthy adult subjects unless otherwise noted. The table is not all-inclusive.

**Interactions and dose recommendations with other medicinal products**

| Medicinal products by therapeutic areas  | Interaction   | Recommendations concerning co-administration  |
|--|---|---|
| <b>ANTIVIRALS, HCV</b>   |   |   |
| <i>Nucleotide analogue polymerase inhibitor</i>  |   |   |
| <b>Sofosbuvir 400 mg once daily</b><br>(daclatasvir 60 mg once daily)<br><br>Study conducted in patients with chronic HCV infection      | ↔ Daclatasvir*<br>AUC: 0.95 (0.82, 1.10)<br>C <sub>max</sub> : 0.88 (0.78, 0.99)<br>C <sub>min</sub> : 0.91 (0.71, 1.16)<br>↔ GS-331007 (major metabolite of sofosbuvir)<br>AUC: 1.0 (0.95, 1.08)<br>C <sub>max</sub> : 0.8 (0.77, 0.90)<br>C <sub>min</sub> : 1.4 (1.35, 1.53) | No dose adjustment of [HP028 trade name] or sofosbuvir is required.                     |
| <i>Other HCV antivirals</i>  |   |   |
| <b>Peginterferon alfa 180 µg once weekly and ribavirin 1000 mg or 1200 mg/day in two divided doses</b><br>(daclatasvir 60 mg once daily) | ↔ Daclatasvir<br>AUC: ↔*<br>C <sub>max</sub> : ↔*<br>C <sub>min</sub> : ↔*<br>↔ Peginterferon alfa  | No dose adjustment of [HP028 trade name], peginterferon alfa, or ribavirin is required. |

| Medicinal products by therapeutic areas  | Interaction  | Recommendations concerning co-administration  |
|--|--|---|
| Study conducted in patients with chronic HCV infection   | C <sub>min</sub> : ↔*<br>↔ Ribavirin<br>AUC: 0.94 (0.80, 1.11)<br>C <sub>max</sub> : 0.94 (0.79, 1.11)<br>C <sub>min</sub> : 0.98 (0.82, 1.17)   |   |
| <b>ANTIVIRALS, HIV or HBV</b>  |  |   |
| <i>Protease inhibitors (PIs)</i>   |  |   |
| <b>Atazanavir 300 mg/ritonavir 100 mg once daily</b>   | ↑ Daclatasvir<br>AUC*: 2.10 (1.95, 2.26)<br>C <sub>max</sub> *: 1.35 (1.24, 1.47)<br>C <sub>min</sub> *: 3.65 (3.25, 4.11)<br>CYP3A4 inhibition by ritonavir<br>*results are dose-normalised to 60 mg dose.                                      | The dose of daclatasvir should be reduced when co-administered with atazanavir/ritonavir, atazanavir/cobicistat or other strong inhibitors of CYP3A4 (see section 4.2).   |
| <b>Atazanavir/cobicistat</b>   | Interaction not studied.<br><i>Expected due to CYP3A4 inhibition by atazanavir/cobicistat:</i><br>↑ Daclatasvir  |   |
| <b>Darunavir 800 mg/ritonavir 100 mg once daily</b><br>(daclatasvir 30 mg once daily)                  | ↑ Daclatasvir<br>AUC: 1.41 (1.32, 1.50)<br>C <sub>max</sub> : 0.77 (0.70, 0.85)<br>↔ Darunavir<br>AUC: 0.90 (0.73, 1.11)<br>C <sub>max</sub> : 0.97 (0.80, 1.17)<br>C <sub>min</sub> : 0.98 (0.67, 1.44)   | The dose of daclatasvir should be reduced when co-administered with darunavir/ritonavir, or other strong inhibitors of CYP3A4 (see section 4.2). However, no dose reduction is envisaged when given with darunavir/cobicistat. No dose adjustment of darunavir/ritonavir or darunavir/cobicistat is required. |
| <b>Darunavir/cobicistat</b>  | Interaction not studied.<br><i>Expected:</i><br>↔ Daclatasvir  |   |
| <b>Lopinavir 400 mg/ritonavir 100 mg twice daily</b><br>(daclatasvir 30 mg once daily)                 | ↔ Daclatasvir<br>AUC: 1.15 (1.07, 1.24)<br>C <sub>max</sub> : 0.67 (0.61, 0.74)<br>↔ Lopinavir<br>AUC: 1.15 (0.77, 1.72)<br>C <sub>max</sub> : 1.22 (1.06, 1.41)<br>C <sub>min</sub> : 1.54 (0.46, 5.07)   | The dose of daclatasvir should be reduced when co-administered with lopinavir/ritonavir, or other strong inhibitors of CYP3A4 (see section 4.2). No dose adjustment of lopinavir/ritonavir is required.   |
| <i>Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)</i>                                  |  |   |
| <b>Tenofovir disoproxil 245 mg once daily</b><br>(daclatasvir 60 mg once daily)                        | ↔ Daclatasvir<br>AUC: 1.10 (1.01, 1.21)<br>C <sub>max</sub> : 1.06 (0.98, 1.15)<br>C <sub>min</sub> : 1.15 (1.02, 1.30)<br>↔ Tenofovir<br>AUC: 1.10 (1.05, 1.15)<br>C <sub>max</sub> : 0.95 (0.89, 1.02)<br>C <sub>min</sub> : 1.17 (1.10, 1.24) | No dose adjustment of [HP028 trade name] or tenofovir disoproxil is required.   |
| <b>Lamivudine</b><br><b>Zidovudine</b><br><b>Emtricitabine</b><br><b>Abacavir</b><br><b>Didanosine</b> | Interaction not studied.<br><i>Expected:</i><br>↔ Daclatasvir<br>↔ NRTI  | No dose adjustment of [HP028 trade name] or the NRTI is required.   |

| Medicinal products by therapeutic areas   | Interaction  | Recommendations concerning co-administration  |
|---|--|---|
| <b>Stavudine</b>  |  |   |
| <i>Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</i>   |  |   |
| <b>Efavirenz 600 mg once daily</b><br>(daclatasvir 60 mg once daily/)   | ↓ Daclatasvir<br>AUC*: 0.68 (0.60, 0.78)<br>C <sub>max</sub> *: 0.83 (0.76, 0.92)<br>C <sub>min</sub> *: 0.41 (0.34, 0.50)<br>Moderate induction of CYP3A4 by efavirenz<br>*results are dose-normalised to 60 mg dose.   | The dose of daclatasvir should be increased when co-administered with efavirenz (see section 4.2).                                    |
| <b>Etravirine</b><br><b>Nevirapine</b>  | ↓ Daclatasvir<br>Moderate induction of CYP3A4 by etravirine or nevirapine  | The dose of daclatasvir should be increased when co-administered with etravirine or nevirapine (see section 4.2).                     |
| <b>Rilpivirine</b>  | Interaction not studied.<br><i>Expected:</i><br>↔ Daclatasvir<br>↔ Rilpivirine   | No dose adjustment of [HP028 trade name] or rilpivirine is required.  |
| <i>Integrase inhibitors</i>   |  |   |
| <b>Dolutegravir 50 mg once daily</b><br>(daclatasvir 60 mg once daily)  | ↔ Daclatasvir<br>AUC: 0.98 (0.83, 1.15)<br>C <sub>max</sub> : 1.03 (0.84, 1.25)<br>C <sub>min</sub> : 1.06 (0.88, 1.29)<br>↑ Dolutegravir<br>AUC: 1.33 (1.11, 1.59)<br>C <sub>max</sub> : 1.29 (1.07, 1.57)<br>C <sub>min</sub> : 1.45 (1.25, 1.68)<br>Inhibition of P-gp and BCRP by daclatasvir. | No dose adjustment of [HP028 trade name] or dolutegravir is required.   |
| <b>Raltegravir</b>  | Interaction not studied.<br><i>Expected:</i><br>↔ Daclatasvir<br>↔ Raltegravir   | No dose adjustment of [HP028 trade name] or raltegravir is required.  |
| <b>Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil</b><br><br><b>Other cobicistat-containing regimens</b> ( <i>except darunavir/cobicistat, see above</i> ) | ↑ Daclatasvir<br>CYP3A4 inhibition by cobicistat   | The dose of daclatasvir should be reduced when co-administered with cobicistat or other strong inhibitors of CYP3A4 (see section 4.2) |
| <i>Fusion inhibitor</i>   |  |   |
| <b>Enfuvirtide</b>  | Interaction not studied.<br><i>Expected:</i><br>↔ Daclatasvir<br>↔ Enfuvirtide   | No dose adjustment of [HP028 trade name] or enfuvirtide is required.  |
| <b>ACID REDUCING AGENTS</b>   |  |   |
| <i>H<sub>2</sub>-receptor antagonists</i>   |  |   |
| <b>Famotidine 40 mg single dose</b><br>(daclatasvir 60 mg single dose)  | ↔ Daclatasvir<br>AUC: 0.82 (0.70, 0.96)<br>C <sub>max</sub> : 0.56 (0.46, 0.67)<br>C <sub>min</sub> : 0.89 (0.75, 1.06)<br>Increase in gastric pH  | No dose adjustment of [HP028 trade name] is required.   |

| Medicinal products by therapeutic areas  | Interaction   | Recommendations concerning co-administration  |
|--|---|---|
| <i>Proton pump inhibitors</i>  |   |   |
| <b>Omeprazole 40 mg once daily</b><br>(daclatasvir 60 mg single dose)                    | ↔ Daclatasvir<br>AUC: 0.84 (0.73, 0.96)<br>C <sub>max</sub> : 0.64 (0.54, 0.77)<br>C <sub>min</sub> : 0.92 (0.80, 1.05)<br>Increase in gastric pH   | No dose adjustment of [HP028 trade name] is required.   |
| <b>ANTIBACTERIALS</b>  |   |   |
| <b>Clarithromycin</b><br><b>Telithromycin</b>  | Interaction not studied.<br><i>Expected due to CYP3A4 inhibition by the antibacterial:</i><br>↑ Daclatasvir   | The dose of daclatasvir should be reduced when co-administered with clarithromycin, telithromycin or other strong inhibitors of CYP3A4 (see section 4.2).   |
| <b>Erythromycin</b>  | Interaction not studied.<br><i>Expected due to CYP3A4 inhibition by the antibacterial:</i><br>↑ Daclatasvir   | Administration of [HP028 trade name] with erythromycin may result in increased concentrations of daclatasvir. Caution is advised.   |
| <b>Azithromycin</b><br><b>Ciprofloxacin</b>  | Interaction not studied.<br><i>Expected:</i><br>↔ Daclatasvir<br>↔ Azithromycin or Ciprofloxacin  | No dose adjustment of [HP028 trade name] or azithromycin or ciprofloxacin is required.  |
| <b>ANTICOAGULANTS</b>  |   |   |
| <b>Dabigatran etexilate</b>  | Interaction not studied.<br><i>Expected due to inhibition of P-gp by daclatasvir:</i><br>↑ Dabigatran etexilate   | Safety monitoring is advised when initiating treatment with [HP028 trade name] in patients receiving dabigatran etexilate or other intestinal P-gp substrates that have a narrow therapeutic range.                                     |
| <b>Warfarin or other vitamin K antagonists</b>   | Interaction not studied.<br><i>Expected:</i><br>↔ Daclatasvir<br>↔ Warfarin   | No dose adjustment of [HP028 trade name] or warfarin is required. Close monitoring of INR values is recommended with all vitamin K antagonists. This is due to liver function that may change during treatment with [HP028 trade name]. |
| <b>ANTICONVULSANTS</b>   |   |   |
| <b>Carbamazepine</b><br><b>Oxcarbazepine</b><br><b>Phenobarbital</b><br><b>Phenytoin</b> | Interaction not studied.<br><i>Expected due to CYP3A4 induction by the anticonvulsant:</i><br>↓ Daclatasvir   | Co-administration of [HP028 trade name] with carbamazepine, oxcarbazepine, phenobarbital, phenytoin or other strong inducers of CYP3A4 is contraindicated (see section 4.3).  |
| <b>ANTIDEPRESSANTS</b>   |   |   |
| <i>Selective serotonin reuptake inhibitors</i>   |   |   |
| <b>Escitalopram 10 mg once daily</b><br>(daclatasvir 60 mg once daily)                   | ↔ Daclatasvir<br>AUC: 1.12 (1.01, 1.26)<br>C <sub>max</sub> : 1.14 (0.98, 1.32)<br>C <sub>min</sub> : 1.23 (1.09, 1.38)<br>↔ Escitalopram<br>AUC: 1.05 (1.02, 1.08)<br>C <sub>max</sub> : 1.00 (0.92, 1.08)<br>C <sub>min</sub> : 1.10 (1.04, 1.16) | No dose adjustment of [HP028 trade name] or escitalopram is required.   |



| Medicinal products by therapeutic areas                                  | Interaction   | Recommendations concerning co-administration  |
|--|---|---|
| <b>ANTIFUNGALS</b>   |   |   |
| <b>Ketoconazole 400 mg once daily</b><br>(daclatasvir 10 mg single dose) | ↑ Daclatasvir<br>AUC: 3.00 (2.62, 3.44)<br>C <sub>max</sub> : 1.57 (1.31, 1.88)<br>CYP3A4 inhibition by ketoconazole                                  | The dose of daclatasvir should be reduced when co-administered with ketoconazole or other strong inhibitors of CYP3A4 (see section 4.2).  |
| <b>Itraconazole</b><br><b>Posaconazole</b><br><b>Voriconazole</b>        | Interaction not studied.<br><i>Expected due to CYP3A4 inhibition by the antifungal:</i><br>↑ Daclatasvir  |   |
| <b>Fluconazole</b>   | Interaction not studied.<br><i>Expected due to CYP3A4 inhibition by the antifungal:</i><br>↑ Daclatasvir<br>↔ Fluconazole                             |   |
| <b>ANTIMYCOBACTERIALS</b>  |   |   |
| <b>Rifampicin 600 mg once daily</b><br>(daclatasvir 60 mg single dose)   | ↓ Daclatasvir<br>AUC: 0.21 (0.19, 0.23)<br>C <sub>max</sub> : 0.44 (0.40, 0.48)<br>CYP3A4 induction by rifampicin                                     | Co-administration of [HP028 trade name] with rifampicin, rifabutin, rifapentine or other strong inducers of CYP3A4 is contraindicated (see section 4.3).  |
| <b>Rifabutin</b><br><b>Rifapentine</b>                                   | Interaction not studied.<br><i>Expected due to CYP3A4 induction by the antimycobacterial:</i><br>↓ Daclatasvir  |   |
| <b>CARDIOVASCULAR AGENTS</b>   |   |   |
| <i>Antiarrhythmics</i>   |   |   |
| <b>Digoxin 0.125 mg once daily</b><br>(daclatasvir 60 mg once daily)     | ↑ Digoxin<br>AUC: 1.27 (1.20, 1.34)<br>C <sub>max</sub> : 1.65 (1.52, 1.80)<br>C <sub>min</sub> : 1.18 (1.09, 1.28)<br>P-gp inhibition by daclatasvir | Digoxin should be used with caution when co-administered with [HP028 trade name]. The lowest dose of digoxin should be initially prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect. |
| <b>Amiodarone</b>  | Interaction not studied.  | Use only if no other alternative is available. Close monitoring is recommended if this medicinal product is administered with [HP028 trade name] in combination with sofosbuvir (see sections 4.4 and 4.8).   |
| <i>Calcium channel blockers</i>  |   |   |
| <b>Diltiazem</b><br><b>Nifedipine</b><br><b>Amlodipine</b>               | Interaction not studied.<br><i>Expected due to CYP3A4 inhibition by the calcium channel blocker:</i><br>↑ Daclatasvir                                 | Caution is advised if [HP028 trade name] is co-administered with calcium channel blockers.  |
| <b>Verapamil</b>   | Interaction not studied.<br><i>Expected due to CYP3A4 and P-gp inhibition by verapamil:</i><br>↑ Daclatasvir  | Caution is advised if [HP028 trade name] is co-administered with calcium channel blockers.  |

| Medicinal products by therapeutic areas  | Interaction  | Recommendations concerning co-administration  |
|--|--|---|
| <b>CORTICOSTEROIDS</b>   |  |   |
| <b>Systemic dexamethasone</b>  | Interaction not studied.<br><i>Expected due to CYP3A4 induction by dexamethasone:</i><br>↓ Daclatasvir   | Co-administration of [HP028 trade name] with systemic dexamethasone or other strong inducers of CYP3A4 is contraindicated (see section 4.3).  |
| <b>HERBAL SUPPLEMENTS</b>  |  |   |
| <b>St. John's wort</b> ( <i>Hypericum perforatum</i> )   | Interaction not studied.<br><i>Expected due to CYP3A4 induction by St. John's wort:</i><br>↓ Daclatasvir   | Co-administration of [HP028 trade name] with St. John's wort or other strong inducers of CYP3A4 is contraindicated (see section 4.3).   |
| <b>HORMONAL CONTRACEPTIVES</b>   |  |   |
| <b>Ethinylestradiol 35 µg once daily for 21 days + norgestimate 0.180/0.215/0.250 mg once daily for 7/7/7 days</b><br>(daclatasvir 60 mg once daily) | ↔ Ethinylestradiol<br>AUC: 1.01 (0.95, 1.07)<br>C <sub>max</sub> : 1.11 (1.02, 1.20)<br>↔ Norelgestromin<br>AUC: 1.12 (1.06, 1.17)<br>C <sub>max</sub> : 1.06 (0.99, 1.14)<br>↔ Norgestrel<br>AUC: 1.12 (1.02, 1.23)<br>C <sub>max</sub> : 1.07 (0.99, 1.16) | If an oral contraceptive is needed during treatment with [HP028 trade name], it should contain ethinylestradiol 35 µg and norgestimate 0.180/0.215/0.250 mg. Other oral contraceptives have not been studied. |
| <b>IMMUNOSUPPRESSANTS</b>  |  |   |
| <b>Cyclosporine 400 mg single dose</b><br>(daclatasvir 60 mg once daily)   | ↔ Daclatasvir<br>AUC: 1.40 (1.29, 1.53)<br>C <sub>max</sub> : 1.04 (0.94, 1.15)<br>C <sub>min</sub> : 1.56 (1.41, 1.71)<br>↔ Cyclosporine<br>AUC: 1.03 (0.97, 1.09)<br>C <sub>max</sub> : 0.96 (0.91, 1.02)  | No dose adjustment of either medicinal product is required when [HP028 trade name] is co-administered with cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil.                                      |
| <b>Tacrolimus 5 mg single dose</b><br>(daclatasvir 60 mg once daily)   | ↔ Daclatasvir<br>AUC: 1.05 (1.03, 1.07)<br>C <sub>max</sub> : 1.07 (1.02, 1.12)<br>C <sub>min</sub> : 1.10 (1.03, 1.19)<br>↔ Tacrolimus<br>AUC: 1.00 (0.88, 1.13)<br>C <sub>max</sub> : 1.05 (0.90, 1.23)  |   |
| <b>Sirolimus Mycophenolate mofetil</b>   | Interaction not studied.<br><i>Expected:</i><br>↔ Daclatasvir<br>↔ Immunosuppressant   |   |
| <b>LIPID LOWERING AGENTS</b>   |  |   |
| <i>HMG-CoA reductase inhibitors</i>  |  |   |
| <b>Rosuvastatin 10 mg single dose</b><br>(daclatasvir 60 mg once daily)  | ↑ Rosuvastatin<br>AUC: 1.58 (1.44, 1.74)<br>C <sub>max</sub> : 2.04 (1.83, 2.26)<br>Inhibition of OATP 1B1 and BCRP by daclatasvir   | Caution should be used when [HP028 trade name] is co-administered with rosuvastatin or other substrates of OATP 1B1 or BCRP.  |
| <b>Atorvastatin<br/>Fluvastatin<br/>Simvastatin<br/>Pitavastatin</b>   | Interaction not studied.<br><i>Expected due to inhibition of OATP 1B1 and/or BCRP by daclatasvir:</i>  |   |

| Medicinal products by therapeutic areas  | Interaction  | Recommendations concerning co-administration   |
|--|--|--|
| <b>Pravastatin</b>   | ↑ Concentration of statin  |  |
| <b>NARCOTIC ANALGESICS</b>   |  |  |
| <b>Buprenorphine/naloxone, 8/2 mg to 24/6 mg once daily individualized dose*</b><br>(daclatasvir 60 mg once daily)<br>* Evaluated in opioid-dependent adults on stable buprenorphine/naloxone maintenance therapy. | ↔ Daclatasvir<br>AUC: ↔*<br>C <sub>max</sub> : ↔*<br>C <sub>min</sub> : ↔*<br><br>↑ Buprenorphine<br>AUC: 1.37 (1.24, 1.52)<br>C <sub>max</sub> : 1.30 (1.03, 1.64)<br>C <sub>min</sub> : 1.17 (1.03, 1.32)<br>↑ Norbuprenorphine<br>AUC: 1.62 (1.30, 2.02)<br>C <sub>max</sub> : 1.65 (1.38, 1.99)<br>C <sub>min</sub> : 1.46 (1.12, 1.89)<br>*Compared with historical data. | No dose adjustment of [HP028 trade name] or buprenorphine may be required, but it is recommended that patients should be monitored for signs of opiate toxicity. |
| <b>Methadone, 40-120 mg once daily individualized dose*</b><br>(daclatasvir 60 mg once daily)<br>* Evaluated in opioid-dependent adults on stable methadone maintenance therapy.                                   | ↔ Daclatasvir<br>AUC: ↔*<br>C <sub>max</sub> : ↔*<br>C <sub>min</sub> : ↔*<br>↔ R-methadone<br>AUC: 1.08 (0.94, 1.24)<br>C <sub>max</sub> : 1.07 (0.97, 1.18)<br>C <sub>min</sub> : 1.08 (0.93, 1.26)<br>*Compared with historical data.   | No dose adjustment of [HP028 trade name] or methadone is required.   |
| <b>SEDATIVES</b>   |  |  |
| <i>Benzodiazepines</i>   |  |  |
| <b>Midazolam 5 mg single dose</b><br>(daclatasvir 60 mg once daily)  | ↔ Midazolam<br>AUC: 0.87 (0.83, 0.92)<br>C <sub>max</sub> : 0.95 (0.88, 1.04)  | No dose adjustment of midazolam, other benzodiazepines or other CYP3A4 substrates is required when co-administered with [HP028 trade name].                      |
| <b>Triazolam<br/>Alprazolam</b>  | Interaction not studied.<br><i>Expected:</i><br>↔ Triazolam<br>↔ Alprazolam  |  |

No clinically relevant effects on the pharmacokinetics of either medicinal product are expected when daclatasvir is co-administered with any of the following: PDE-5 inhibitors, medicinal products in the ACE inhibitor class (e.g. enalapril), medicinal products in the angiotensin II receptor antagonist class (e.g. losartan, irbesartan, olmesartan, candesartan, valsartan), disopyramide, propafenone, flecainide, mexilitine, quinidine or antacids.

### *Paediatric population*

Interaction studies have only been performed in adults.

## **4.6 Fertility, pregnancy and breastfeeding**

### *Women of childbearing potential*

Pregnancy should be avoided in women treated with daclatasvir. Use of highly effective contraception should be continued for 5 weeks after completion of therapy with [HP028 trade name] (see section 4.5 for additional information on use with hormonal contraceptives).

### ***Pregnancy***

There are no data from the use of daclatasvir in pregnant women. Studies of daclatasvir in animals have shown embryotoxic and teratogenic effects (see section 5.3).

The potential risk for humans is unknown.

[HP028 trade name] should not be used during pregnancy or in women of childbearing potential not using contraception (see section 4.4). Use of highly effective contraception should be continued for 5 weeks after completion of therapy with (see section 4.5).

Since [HP028 trade name] must be used in combination with sofosbuvir, the contraindications and warnings for this medicinal product are applicable.

### ***Breastfeeding***

It is not known whether daclatasvir is excreted in human milk. Available pharmacokinetic and toxicological data in animals have shown excretion of daclatasvir and metabolites in milk (see section 5.3). A risk to the newborn/infant cannot be excluded. Mothers should be instructed not to breastfeed if they are taking [HP028 trade name].

### ***Fertility***

No human data on the effect of daclatasvir on fertility are available. In rats, no effect on mating or fertility was seen (see section 5.3).

## **4.7 Effects on ability to drive and use machines**

Dizziness and tiredness have been reported during treatment with daclatasvir in combination with other hepatitis C medicines. If affected, patients should not drive or operate machinery.

## **4.8 Undesirable effects**

### ***Summary of the safety profile***

The most frequently reported adverse reactions with daclatasvir plus sofosbuvir are fatigue, headache and nausea, usually mild. Anaemia was also reported very commonly from studies where daclatasvir was given with sofosbuvir with or without ribavirin.

### ***Tabulated list of adverse reactions***

Adverse reactions to [HP028 trade name] from controlled trials with daclatasvir in combination with sofosbuvir (with or without ribavirin) or peginterferon alfa and ribavirin are presented in the table below.

Adverse drug reactions are listed by system organ class (SOC) and frequency. Frequency categories are defined as follows: very common (at least 1 in 10), common (1 in 100 to 1 in 10) and uncommon (1 in 1000 to 1 in 100).

#### **Blood and lymphatic system disorders**

Very common    anaemia

#### **Metabolism and nutrition disorders**

Common        decreased appetite

#### **Psychiatric disorders**

Common        insomnia, irritability

#### **Nervous system disorders**

Very common    headache

Common        dizziness, migraine

### **Vascular disorders**

Common hot flush

### **Respiratory, thoracic and mediastinal disorders**

Common dyspnoea, dyspnoea exertional, cough, nasal congestion

### **Gastrointestinal disorders**

Very common nausea

Common diarrhoea, vomiting, abdominal pain, gastroesophageal reflux disease, constipation, dry mouth, flatulence

### **Skin and subcutaneous tissue disorders**

Common rash, alopecia, pruritus, dry skin

### **Musculoskeletal and connective tissue disorders**

Common arthralgia, myalgia

### **General disorders**

Very common fatigue

### *Laboratory abnormalities*

In clinical studies of daclatasvir in combination with sofosbuvir with or without ribavirin, 2% of patients had Grade 3 haemoglobin decreases; all of these patients received daclatasvir + sofosbuvir + ribavirin. Grade 3/4 increases in total bilirubin were observed in 5% of patients (all in patients with HIV coinfection who were receiving concomitant atazanavir, with Child-Pugh A, B, or C cirrhosis, or who were post-liver transplant).

### ***Description of selected adverse reactions***

#### *Cardiac arrhythmias*

Cases of severe bradycardia and heart block have been observed when daclatasvir is used in combination with sofosbuvir and concomitant amiodarone and/or other drugs that lower the heart rate (see sections 4.4 and 4.5).

#### ***Reporting of suspected adverse reactions***

Health care providers are asked to report adverse reactions that may be linked to a medicine, to the marketing authorisation holder, or, if available, to the national reporting system. Reports of suspected adverse reactions to a medicine are important for the monitoring of the medicine's benefits and risks.

## **4.9 Overdose**

### *Symptoms*

There is limited experience of accidental overdose of daclatasvir in clinical studies. In phase 1 clinical studies, healthy subjects who received up to 100 mg once daily for up to 14 days or single doses up to 200 mg had no unexpected adverse reactions.

### *Treatment*

There is no known antidote for overdose of daclatasvir. Treatment of overdose with daclatasvir should consist of general supportive measures, including monitoring of vital signs, and observation of the patient's clinical status. Because daclatasvir is highly protein bound (99%) and has a molecular weight >500, dialysis is unlikely to significantly reduce plasma concentrations of daclatasvir.

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Direct-acting antiviral, ATC code: J05AP07

#### **Mechanism of action**

Daclatasvir is an inhibitor of non-structural protein 5A (NS5A), a multifunctional protein that is an essential component of the HCV replication complex. Daclatasvir inhibits both viral RNA replication and virion assembly.

#### **Clinical efficacy and safety**

A WHO-commissioned systematic review identified 142 clinical studies that evaluated the safety and efficacy of various FDA- and EMA-approved DAA regimens, including sofosbuvir/daclatasvir.

#### ***Sofosbuvir/daclatasvir in HCV infected adults without cirrhosis***

In a combined analysis of treatment-naïve and treatment-experienced persons treated with sofosbuvir/daclatasvir, the pooled SVR rates exceeded 92% for infection with genotypes 1, 2, 3 and 4. Data from an observational study (MSF demonstration project) provided information on the less commonly reported genotypes 5 and 6. A total of eight persons with genotype 5 and 123 persons with genotype 6 infection were treated with sofosbuvir/daclatasvir for 12 weeks. SVR rates were 88% and 94% for genotypes 5 and 6 respectively.

#### ***Sofosbuvir/daclatasvir in HCV infected adults with compensated cirrhosis***

In a combined analysis of treatment-naïve and treatment-experienced persons with compensated cirrhosis (Child Pugh A or B) treated with sofosbuvir/daclatasvir for 12 weeks, the pooled SVR rates exceeded 93% for infection with genotypes 1 and 2. SVR rates for infection with genotype 3 were low, ranging from 79% to 82%. However, after 24 weeks of treatment, SVR rates increased to 90%. Data from an observational study (MSF demonstration project) provided information on genotypes 5 and 6, and real-world data from Egypt provided information on genotype 4. One cirrhotic person with genotype 5 infection treated with sofosbuvir/daclatasvir for 12 weeks reached SVR. Among 185 cirrhotic persons with genotype 6 infection treated with sofosbuvir/daclatasvir for 12 weeks, 92% reached SVR. Cirrhotic persons with genotype 4 infection had SVR rates that exceeded 98% after 12 weeks of treatment.

#### ***Sofosbuvir/daclatasvir in HCV infected adults with decompensated cirrhosis***

There are currently insufficient data to provide definitive treatment guidelines for HCV infected adults with decompensated cirrhosis (Child Pugh C). It is recommended that such individuals are treated with sofosbuvir/daclatasvir for 24 weeks using the same regimen as used for individuals with compensated cirrhosis.

#### ***HCV/HIV co-infection***

HCV treatment outcomes with daclatasvir/sofosbuvir are comparable in persons with HIV/HCV coinfection to those with HCV mono-infection. Because DAAs are safe and effective for people with HIV/HCV, there is no longer any need to consider them as a special or difficult-to-treat population. However, there are important DDIs (drug-drug interactions) with pangenotypic HCV regimens and antiretroviral therapies for HIV. Therefore, checking for DDIs between HCV and HIV medications should be emphasized. The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. See Section 4.5.

#### ***Safety of sofosbuvir/daclatasvir***

Treatment discontinuation due to adverse events was very low in persons without and with cirrhosis (<1%). Similar results were observed in treatment-naïve and treatment-experienced persons.

### Long term efficacy data

In a follow-up study of 258 patients who achieved SVR12 with daclatasvir and sofosbuvir with a median duration of post-SVR12 follow-up of 38 months, no relapses occurred (with relapses defined as confirmed or last available HCV RNA  $\geq$  LLOQ).

#### *Impact of baseline NS5A RAVs on cure rates*

Baseline NS5A resistance-associated variants (RAVs) had no major impact on cure rates in patients treated with sofosbuvir + daclatasvir, with the exception of the Y93H RAV in genotype 3 infection (seen in 16/192 [8%] of patients). The SVR12 rate in genotype-3 infected patients with this RAV is reduced (in practice as relapse after end of treatment response), especially in patients with cirrhosis. The overall cure rate for genotype-3 infected patients who were treated for 12 weeks with sofosbuvir + daclatasvir in the presence and absence of the Y93H RAV was 7/13 (54%) and 134/145 (92%), respectively.

### Paediatric population

A WHO-commissioned systematic review and meta-analysis of the efficacy and safety of key DAA regimens was undertaken for adolescents (12–18 years), older children (6–11 years) and younger children (3–5 years) with chronic hepatitis C virus infection, based on the same age groupings used in the trials for regulatory approval. There were 49 studies (three RCTs, 28 non-RCTs and 18 observational studies). Together, they reported treatment experience in 1891 adolescents (35 study arms), 472 older children (13 study arms) and 167 younger children (7 study arms). There were no placebo-controlled RCTs, and findings were based on summary estimates of SVR cure rates by regimen in the three age groups. However, these were considered informative because spontaneous clearance is rare in the absence of treatment. Data on serious adverse events and treatment discontinuations were considered more informative than adverse events alone because of the lack of a comparison group. The majority of participants were non-cirrhotic (1786, 70.6%), treatment-naïve (1825, 72.1%), and with non-GT3 infection (1453, 57.4%).

Overall, sustained virological response rates 12 weeks after the end of treatment (SVR12) were high ( $\geq$ 95%) in all age groups and for the key pangenotypic DAA regimens (sofosbuvir/daclatasvir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) as well as for sofosbuvir/ledipasvir. In particular, among the 183 adolescents (12 to 17 years) who received sofosbuvir/daclatasvir, SVR12 was 99% (96–100). Among the 34 older children (6 to 11 years) who received sofosbuvir/daclatasvir, SVR12 was 100% (94–100). There were no study data for sofosbuvir/daclatasvir in younger children (3 to 5 years).

The rate of any adverse event with pangenotypic DAA regimens was higher for children ages 3–5 years (72%) than for those ages 6–11 years (53%) or adolescents (50%), but serious adverse events and treatment discontinuations were uncommon (<1%), except in young children (6.6%) because of the poor palatability of the oral formulation of sofosbuvir/velpatasvir in this group. Less than half of the studies (22/49 (44.9%)) reported information on comorbidities. There were 15 persons with cirrhosis across nine studies, 304 persons who were treatment-experienced across 21 studies and 157 persons with GT3 infection across eight studies. There were no studies of sofosbuvir/daclatasvir in children or adolescents reported from sub-Saharan Africa, where HCV genotype 4 non-a/d subtypes are endemic in some regions, as well as other genotypes (including genotype 1 and 3) that frequently contain resistance-associated substitutions in the NS5A regions. This may contribute to higher rates of treatment failure with sofosbuvir/daclatasvir.

## 5.2 Pharmacokinetic properties

The absorption characteristics of [HP028 trade name] have been determined after administration of one (1) tablet in healthy volunteers in the fasted state as follows:

| Pharmacokinetic variable            | Arithmetic mean $\pm$ standard deviation (*) |
|-------------------------------------|--|
|                                     | Daclatasvir                                  |
| Maximum concentration ( $C_{max}$ ) | 1 936 $\pm$ 541 (1868) ng/mL                 |

|   |                                 |
|---|---------------------------------|
| Area under the curve (AUC <sub>0-∞</sub> ), a measure of the extent of absorption | 21 821 ± 10 295 (20289) ng.h/mL |
| Time to attain maximum concentration (t <sub>max</sub> ) <sup>#</sup>             | 1.25 (0.67 – 3.5) h             |

| <b>Daclatasvir</b>                         |  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
|--|--|----------------------|----------------------|------------------|------------------|--------------------|------|------|-----|-----------------|-----------|-----------|-----|
| <b>General</b>                             |  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
|  | The pharmacokinetic properties of daclatasvir were evaluated in healthy adult subjects and in patients with chronic HCV.   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| <b>Absorption</b>                          |  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Absolute bioavailability                   | The absolute bioavailability of the tablet formulation is 67%.   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Oral bioavailability                       | At least 67%.  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Food effect                                | <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th style="text-align: center;">AUC<sub>(0-∞)</sub></th> <th style="text-align: center;">C<sub>max</sub></th> <th style="text-align: center;">T<sub>max</sub></th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">With high-fat meal</td> <td style="text-align: center;">23%↓</td> <td style="text-align: center;">28%↓</td> <td style="text-align: center;">NA*</td> </tr> <tr> <td style="text-align: center;">With light meal</td> <td style="text-align: center;">No change</td> <td style="text-align: center;">No change</td> <td style="text-align: center;">NA*</td> </tr> </tbody> </table> |                      | AUC <sub>(0-∞)</sub> | C <sub>max</sub> | T <sub>max</sub> | With high-fat meal | 23%↓ | 28%↓ | NA* | With light meal | No change | No change | NA* |
|  |  | AUC <sub>(0-∞)</sub> | C <sub>max</sub>     | T <sub>max</sub> |                  |                    |      |      |     |                 |           |           |     |
|  | With high-fat meal   | 23%↓                 | 28%↓                 | NA*              |                  |                    |      |      |     |                 |           |           |     |
| With light meal                            | No change  | No change            | NA*                  |                  |                  |                    |      |      |     |                 |           |           |     |
| <b>Distribution</b>                        |  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Volume of distribution (mean)              | Approximately 47 L.  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Plasma protein binding                     | Approximately 99% (independent of dose between 1 mg to 100 mg)   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Tissue distribution                        | Active and passive transport into hepatocytes.   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| <b>Metabolism</b>                          |  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
|  | Substrate of CYP3A with CYP3A4 being the major isoform responsible for metabolism.   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Active metabolite(s)                       | None.  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| <b>Elimination</b>                         |  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| General note                               | Daclatasvir is mainly cleared by the liver.  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Elimination half life                      | 12 to 15 h   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Mean systemic clearance (Cl/F)             | 4.24 L/h   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| % of dose excreted in urine                | 6.6% (primarily as unchanged drug)   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| % of dose excreted in faeces               | 88% (53% as unchanged drug)  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| <b>Pharmacokinetic linearity</b>           | Daclatasvir C <sub>max</sub> , AUC and C <sub>min</sub> increase in a near dose-proportional manner  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| <b>Drug interactions (<i>in vitro</i>)</b> | NA*  |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Transporters                               | <i>In vitro</i> and <i>in vivo</i> studies showed that daclatasvir is a substrate of P-gp. Daclatasvir is an inhibitor of P-gp, OATP 1B1 and BCRP. Active transport into hepatocytes by OCT1 and other unidentified uptake transporters.<br><i>In vitro</i> daclatasvir is an inhibitor of renal uptake transporters, OAT1 and 3, and OCT2, but is not expected to have a clinical effect on the pharmacokinetics of substrates of these transporters.   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |
| Metabolizing enzymes                       | <i>In vitro</i> and <i>in vivo</i> studies demonstrate that daclatasvir is a substrate of CYP3A, with CYP3A4 being the major CYP isoform responsible for the metabolism. Daclatasvir <i>in vitro</i> did not inhibit CYP enzymes 1A2, 2B6, 2C8, 2C9, 2C19, or 2D6.   |                      |                      |                  |                  |                    |      |      |     |                 |           |           |     |

\*Information not available



### ***Pharmacokinetics in special clinical situations***

#### ***Renal impairment***

The pharmacokinetics of daclatasvir following a single 60 mg oral dose were studied in non-HCV infected subjects with renal impairment. Daclatasvir unbound AUC was estimated to be 18%, 39% and 51% higher for subjects with creatinine clearance (CL<sub>cr</sub>) values of 60, 30 and 15 ml/min, respectively, relative to subjects with normal renal function. Subjects with end-stage renal disease requiring haemodialysis had a 27% increase in daclatasvir AUC and a 20% increase in unbound AUC compared to subjects with normal renal function.

#### ***Hepatic impairment***

The pharmacokinetics of daclatasvir following a single 30 mg oral dose were studied in non-HCV infected subjects with mild (Child-Pugh A), moderate (Child-Pugh B), and severe (Child-Pugh C) hepatic impairment compared with unimpaired subjects. The C<sub>max</sub> and AUC of total daclatasvir (free and protein-bound drug) were lower in subjects with hepatic impairment; however, hepatic impairment did not have a clinically significant effect on the free drug concentrations of daclatasvir.

#### ***Elderly***

Population pharmacokinetic analysis of data from clinical studies indicated that age had no apparent effect on the pharmacokinetics of daclatasvir.

#### ***Gender***

Population pharmacokinetic analysis identified gender as a statistically significant covariate on daclatasvir apparent oral clearance (CL/F) with female subjects having slightly lower CL/F, but the magnitude of the effect on daclatasvir exposure is not clinically important.

#### ***Race***

Population pharmacokinetic analysis of data from clinical studies identified race (categories “other” [patients who are not white, black or Asian] and “black”) as a statistically significant covariate on daclatasvir apparent oral clearance (CL/F) and apparent volume of distribution (V<sub>c</sub>/F) resulting in slightly higher exposures compared to white patients, but the magnitude of the effect on daclatasvir exposure is not clinically important.

## **5.3 Preclinical safety data**

### ***General toxicity***

In repeat-dose toxicology studies in animals, hepatic effects (Kupffer-cell hypertrophy/ hyperplasia, mononuclear cell infiltrates and bile duct hyperplasia) and adrenal gland effects (changes in cytoplasmic vacuolation and adrenal cortical hypertrophy/hyperplasia) were observed at exposures similar or slightly higher than the clinical AUC exposure. In dogs, bone marrow hypocellularity with correlating clinical pathology changes were observed at exposures 9-fold the clinical AUC exposure. None of these effects have been observed in humans.

### ***Mutagenicity/ Carcinogenicity***

Daclatasvir was not carcinogenic in mice or in rats at exposures 8-fold or 4-fold, respectively, the clinical AUC exposure. No evidence of mutagenic or clastogenic activity was observed in *in vitro* mutagenesis (Ames) tests, mammalian mutation assays in Chinese hamster ovary cells, or in an *in vivo* oral micronucleus study in rats.

### ***Reproductive toxicity***

Daclatasvir is embryotoxic and teratogenic in rats and rabbits at exposures at or above 4-fold (rat) and 16-fold (rabbit) the clinical AUC exposure. Developmental toxicity consisted of increased embryofetal lethality, reduced fetal body weights and increased incidence of fetal malformations and variations. In rats, malformations mainly affected the brain, skull, eyes, ears, nose, lip, palate or limbs and in rabbits, the ribs and cardiovascular area. Maternal toxicity including mortality, abortions, adverse clinical signs, decreases in

body weight and food consumption was noted in both species at exposures 25-fold (rat) and 72-fold (rabbit) the clinical AUC exposure.

In a study of pre- and post-natal development in rats, there was neither maternal nor developmental toxicity at doses up to 50 mg/kg/day, associated with AUC values 2-fold the clinical AUC exposure. At the highest dose (100 mg/kg/day), maternal toxicity included mortality and dystocia; developmental toxicity included slight reductions in offspring viability in the peri- and neonatal periods; and reductions in birth weight that persisted into adulthood. The AUC value associated with this dose is 4-fold the clinical AUC exposure.

Daclatasvir had no effects on fertility in female rats at any dose tested. The highest AUC value in unaffected females was 18-fold the clinical AUC exposure. In male rats, effects on reproductive endpoints were limited to reduced prostate/seminal vesicle weights, and minimally increased dysmorphic sperm at 200 mg/kg/day; however, neither finding adversely affected fertility nor the number of viable conceptuses sired. The AUC associated with this dose in males is 19-fold the clinical AUC exposure.

Daclatasvir was excreted into the milk of lactating rats with concentrations 1.7- to 2-fold maternal plasma levels.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

*Core tablet:* Anhydrous lactose  
Microcrystalline cellulose  
Croscarmellose sodium  
Colloidal silicon dioxide  
Magnesium stearate

*Film coat:* Polyvinyl alcohol-partially hydrolysed  
Titanium dioxide  
Macrogol/PEG  
Talc

This medicine is essentially 'sodium-free'. It contains less than 1 mmol sodium (23 mg) per tablet.

### 6.2 Incompatibilities

Not applicable

### 6.3 Shelf life

36 months

*In-use shelf life*

*500s count:* Discard the product 30 days after initial opening.

### 6.4 Special precautions for storage

Do not store above 30°C. Store in the original container. Do not remove the desiccant canister from the bottle.

### 6.5 Nature and contents of container

**28's Count:** White, opaque 60cc /33mm HDPE bottle, containing a 1-gram silica gel canister closed with a 33mm- 400 ARGUS polypropylene child-resistant closure with TEKNIPLEX HS 123 induction sealing wad.

**500's Count:** White, opaque 250cc / 53mm HDPE bottle, containing a 1-gram silica gel canister and closed with a cap (53mm- 400 screw polypropylene closure with TEKNIPLEX HS 123 induction sealing wad).

## 6.6 Special precautions for disposal and other handling

Not applicable

## 7. SUPPLIER

Laurus Labs Limited  
2<sup>nd</sup> Floor, Serene Chambers, Road No.7  
Banjara hills, Hyderabad, Telangana – 500034  
India  
Tel. No.: +91-40-3980 4333/23420500  
Fax No.: +91-40-3980 4320  
Email: [rafd@lauruslabs.com](mailto:rafd@lauruslabs.com)

## 8. WHO REFERENCE NUMBER (WHO Prequalification Programme)

HP028

## 9. DATE OF PREQUALIFICATION

18 December 2020

## 10. DATE OF REVISION OF THE TEXT

March 2024

### References

#### General

World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018. Available at:

<https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf>

World Health Organization. Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics. 2022. Available at:

<https://iris.who.int/bitstream/handle/10665/363590/9789240052734-eng.pdf?sequence=1>

Daklinza 30 and 60 mg film-coated tablets: product information. European Medicines Agency; 22 August 2014 ([https://www.ema.europa.eu/en/documents/product-information/daklinza-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/daklinza-epar-product-information_en.pdf)).

Daklinza (daclatasvir) tablets for oral use: highlights of prescribing information. US Food and Drug Administration; February 2017 ([https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/206843s006lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206843s006lbl.pdf)).

#### Section 4.5

University of Liverpool, HEP and HIV Drug interactions, available at:

<http://www.hep-druginteractions.org>

<http://www.hiv-druginteractions.org>

[All links accessed in March 2024]

*Detailed information on this medicine is available on the World Health Organization (WHO) website:*  
<https://extranet.who.int/prequal/medicines/prequalified/finished-pharmaceutical-products>